Selected article for: "causative agent and globally China spread"
Author: Zhong, Jixin; Tang, Jungen; Ye, Cong; Dong, Lingli
Title: The immunology of COVID-19: is immune modulation an option for treatment?
  • Cord-id: mbv45kei
  • Document date: 2020_5_20
    • ID: mbv45kei
    Snippet: In December, 2019, an outbreak of COVID-19 emerged in Wuhan, China and quickly spread globally. As of May 7, 2020, there were 3 672 238 confirmed infections and 254 045 deaths attributed to COVID-19. Evidence has shown that there are asymptomatic carriers of COVID-19 who can transmit the disease to others. The virus incubation time shows a wide range (0–24 days) and the virus displays a high infectivity. It is therefore urgent to develop an effective therapy to treat patients with COVID-19 and
    Document: In December, 2019, an outbreak of COVID-19 emerged in Wuhan, China and quickly spread globally. As of May 7, 2020, there were 3 672 238 confirmed infections and 254 045 deaths attributed to COVID-19. Evidence has shown that there are asymptomatic carriers of COVID-19 who can transmit the disease to others. The virus incubation time shows a wide range (0–24 days) and the virus displays a high infectivity. It is therefore urgent to develop an effective therapy to treat patients with COVID-19 and to control the spread of the causative agent, severe respiratory syndrome coronavirus 2. Repurposing of approved drugs is widely adopted to fight newly emerged diseases such as COVID-19, as these drugs have known pharmacokinetic and safety profiles. As pathological examination has confirmed the involvement of immune hyperactivation and acute respiratory distress syndrome in fatal cases of COVID-19, several disease-modifying anti-rheumatic drugs (DMARDS), such as hydroxychloroquine and tocilizumab, have been proposed as potential therapies for the treatment of COVID-19. In this Review, we discuss the immunological aspects of COVID-19 and the potential implication of DMARDs in treating this disease.

    Search related documents:
    Co phrase search for related documents
    • aberrant immune activation and acute ards respiratory distress syndrome: 1
    • aberrant immune activation and acute sars cov respiratory syndrome coronavirus: 1, 2, 3
    • aberrant immune activation and adaptive immunity: 1
    • acid homology and action mechanism: 1
    • acid homology and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6
    • acid level and action mechanism: 1, 2
    • acid level and acute ards respiratory distress syndrome: 1, 2, 3
    • acid level and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8
    • acid level and acute vivo lung injury: 1
    • action mechanism and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • action mechanism and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • action mechanism and acute toxicity: 1
    • action mechanism and acute vivo lung injury: 1
    • action mechanism and adaptive immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • activator jak signal transducer and acute sars cov respiratory syndrome coronavirus: 1, 2
    • activator jak signal transducer and adaptive immunity: 1
    • active metabolite and acute ards respiratory distress syndrome: 1, 2, 3
    • active metabolite and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute ards respiratory distress syndrome and adaptive immunity: 1, 2, 3, 4, 5, 6, 7